A surge in mergers and acquisitions (M&A) boosted the biopharma market by $36 billion at the end of 2025, a new report finds.  Evaluate’s 2026 Preview Report shows $36 billion was generated through M&A last October and November, largely through biotech buyout. The report predicts M&A will continue to play an important role in the biopharma industry in 2026.  The […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!